title: High-dose therapy and autologous stem cell rescue for poor risk and refractory lymphoma: a single centre experience of 123 patients.
abstract: Over an 8-year period we autografted 123 patient with poor-risk lymphoma. Sixty-three patients had Hodgkin's disease (HD) and 60 non-Hodgkin's lymphoma (NHL). Of the patients with HD, 45 had responsive and 18 resistant disease prior to high-dose therapy. Fifty-three patients with NHL had responsive and seven had resistant disease at the time of transplantation. Seventy-seven patients received autologous bone marrow (BM) rescue, 39 autologous peripheral blood progenitor cell (PBPC) rescue, and seven combined BM and PBPC rescue. High-dose chemotherapy was BEM in 67, BEAM in 39, TBI and cyclophosphamide or etoposide or BCNU in 10, etoposide/mitozantrone in six and etoposide/melphalan in one. There was eight (6.5%) deaths due to treatment-related toxicity, within the first 100 days post-transplantation. Of the patients with HD 41 (65%) are alive at a median follow-up of 39 months (range 2-94). Thirty-three (52%) patients remain in CR. The median DFS of the 63 patients with HD is 34 months (95% CI 7-61). The median DFS for patients transplanted with responsive disease was significantly better than for those transplanted with refractory disease (61 vs 21 months P < 0001). Thirty-five (58%) of the patients with NHL are alive, and 20 (33%) remain in CR. The median DFS for patients transplanted with responsive and refractory disease was 11 months (95% CI 3-19) and 4 months (95% CI 0-9; P = NS) respectively. The median DFS for patients transplanted with HD was significantly better than for patients transplanted with NHL (34 vs 8 months, P < 0.002). In both groups there was no significant difference in DFS in patients receiving one, two, three or more lines of therapy prior to transplantation. In summary, in patients with poor-risk lymphoma who have responsive disease high-dose therapy may result in durable CRs. Conversely, only a small proportion of patients with HD or NHL with resistant disease achieve CR after autologous stem cell rescue.
authors.affiliation: Bone Marrow Transplant Unit, Addenbrooke's NHS Trust, Cambridge, UK.
authors.forename: P
authors.initials: P
authors.lastname: Mahendra
authors.forename: D
authors.initials: D
authors.lastname: Johnson
authors.forename: I M
authors.initials: IM
authors.lastname: Hood
authors.forename: M A
authors.initials: MA
authors.lastname: Scott
authors.forename: P
authors.initials: P
authors.lastname: Barker
authors.forename: G
authors.initials: G
authors.lastname: Bass
authors.forename: H K
authors.initials: HK
authors.lastname: Jestice
authors.forename: D M
authors.initials: DM
authors.lastname: Bloxham
authors.forename: P
authors.initials: P
authors.lastname: Boraks
authors.forename: J Z
authors.initials: JZ
authors.lastname: Wimperis
authors.forename: T P
authors.initials: TP
authors.lastname: Baglin
authors.forename: R E
authors.initials: RE
authors.lastname: Marcus
mesh_terms: D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D008223:Lymphoma / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D014182:Transplantation, Autologous
chemical_list: D000970:Antineoplastic Agents